Lung Cancer

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

Case Reports, Lung Cancer

Third-Line Tyrosine Kinase Inhibitor Therapy Results in 16-Year Remission in a Patient with Stage IV Non–Small-Cell Lung Cancer

Carrie L. Barnhart, PharmD, BCOP, and David F. Christianson, MD

Lung Cancer

2022 Midyear Review: Non–Small-Cell Lung Cancer

Meeting Highlights Online Only

AACR Highlights, Lung Cancer

First-Line Sotorasib Shows Long-Lasting Responses in Metastatic NSCLC with KRAS Mutation

FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

Lung Cancer

Severe Adverse Events from Immune Checkpoint Inhibitor Therapy a Rare Concerning Side Effect

Lung Cancer

KRASᴳ¹²ᶜ Mutation–Positive Advanced NSCLC

Lung Cancer

CodeBreaK 100 Trial Results Demonstrate Sotorasib Conveys Clinical Benefit Across NSCLC Patient Subgroups

Lung Cancer

NSAID Use with Immune Checkpoint Inhibitors Associated with Longer Overall Survival in NSCLC

Lung Cancer

The Effect of Various KRAS Mutations on NSCLC Susceptibility

Lung Cancer

Patterns of Biomarker Testing in Metastatic NSCLC in the Community Oncology Setting

Page 1 of 12
Results 1 - 10 of 114